JP2001518118A - ヒト肥満細胞活性化のモジュレーション - Google Patents

ヒト肥満細胞活性化のモジュレーション

Info

Publication number
JP2001518118A
JP2001518118A JP54597398A JP54597398A JP2001518118A JP 2001518118 A JP2001518118 A JP 2001518118A JP 54597398 A JP54597398 A JP 54597398A JP 54597398 A JP54597398 A JP 54597398A JP 2001518118 A JP2001518118 A JP 2001518118A
Authority
JP
Japan
Prior art keywords
purinoceptor
mast cells
atp
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54597398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518118A5 (cg-RX-API-DMAC7.html
Inventor
ペレッグ,アミーア
ビー シャルマン,エドワード
Original Assignee
アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ filed Critical アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ
Publication of JP2001518118A publication Critical patent/JP2001518118A/ja
Publication of JP2001518118A5 publication Critical patent/JP2001518118A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
JP54597398A 1997-03-25 1998-03-24 ヒト肥満細胞活性化のモジュレーション Ceased JP2001518118A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
US60/041,461 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (2)

Publication Number Publication Date
JP2001518118A true JP2001518118A (ja) 2001-10-09
JP2001518118A5 JP2001518118A5 (cg-RX-API-DMAC7.html) 2005-11-24

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54597398A Ceased JP2001518118A (ja) 1997-03-25 1998-03-24 ヒト肥満細胞活性化のモジュレーション

Country Status (9)

Country Link
US (2) US6372724B1 (cg-RX-API-DMAC7.html)
EP (1) EP1011686B9 (cg-RX-API-DMAC7.html)
JP (1) JP2001518118A (cg-RX-API-DMAC7.html)
AT (1) ATE470441T1 (cg-RX-API-DMAC7.html)
AU (1) AU741713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2288821C (cg-RX-API-DMAC7.html)
DE (1) DE69841711D1 (cg-RX-API-DMAC7.html)
DK (1) DK1011686T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998042353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
DK1187617T3 (da) * 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
WO2006012639A2 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
EP1910535B1 (en) 2005-06-24 2016-08-17 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
CA2680801A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation

Also Published As

Publication number Publication date
ATE470441T1 (de) 2010-06-15
WO1998042353A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
US6372724B1 (en) 2002-04-16
EP1011686B9 (en) 2011-02-09
EP1011686B1 (en) 2010-06-09
EP1011686A4 (en) 2003-03-19
CA2288821A1 (en) 1998-10-01
AU7098598A (en) 1998-10-20
DE69841711D1 (de) 2010-07-22
AU741713B2 (en) 2001-12-06
DK1011686T3 (da) 2010-10-11
US20020055515A1 (en) 2002-05-09
CA2288821C (en) 2008-10-14
EP1011686A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
US6465441B2 (en) Screening method for modulation of human mast cell activation
Bowery et al. (–) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor
Guerrero A2A adenosine receptor agonists and their potential therapeutic applications. An update
Kolachala et al. Purinergic receptors in gastrointestinal inflammation
Partida-Sánchez et al. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity
Sihra et al. Effect of cyclosporin A on the allergen-induced late asthmatic reaction.
Guan et al. Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target
Rabe et al. Theophylline and airway inflammation.
HUP0200026A2 (hu) Eljárás terhelés által indukált asztma kezelésére
Brenner et al. Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556
Michael et al. Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations
Gabriella Matera et al. New treatments for COPD in the elderly
Arm et al. Expression of complement receptors type 1 (CR1) and type 3 (CR3) on circulating granulocytes in experimentally provoked asthma
Kaelin et al. Influence of ethanol on human T-lymphocyte migration
Spitzer et al. Protein tyrosine kinase activity and the influence of gender in phagocytosis and tumor necrosis factor secretion in alveolar macrophages and lung-recruited neutrophils
WO2017157248A1 (zh) 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
US5492898A (en) Method of treating endotoxin effects with 2-methylthio-ATP and analogs
Middleton Jr et al. Cellular mechanisms in the pathogenesis and pathophysiology of asthma
WO1995010287A1 (en) Substituted purine nucleoside analogs and method for treating endotoxin shock
JP2002530355A (ja) 炎症性疾患のための治療剤としてのαEβ7インテグリンのアンタゴニスト
Kadioglu et al. Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion.
Coffey et al. Increased adenosine triphosphatase activity in platelets of asthmatic children
Walker Effects of adenosine on guinea pig pulmonary eosinophils
US5516762A (en) Method of treating endotoxin effects with 2-haloadenosine nucleotide analogs
WO1992017186A1 (en) Compounds that prevent endotoxin shock and method of using the compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106